Application of Nirmatrelvir/Ritonavir in Patients with Chronic Kidney Disease and SARS-CoV-2 Infection

VernacularTitle:奈玛特韦/利托那韦在慢性肾脏病合并新型冠状病毒感染患者中的应用
Author: Baoxian LIANG ^{1
,

2} ; Xiaoyun PANG ; Kewei XIE ; Miaolin CHE ; Qin WANG
Author Information

1. 右江民族医学院附属医院药学部,百色 533000
2. 上海交通大学医学院附属仁济医院药学部,上海 200127
Keywords: Nirmatrelvir/ritonavir; Severe acute respiratory syndrome coronavirus-2 infection; Chronic kidney disease; Dialysis; Drug interactions
From: Herald of Medicine 2024;43(9):1440-1444
CountryChina
Language:Chinese
Abstract: Severe acute respiratory syndrome coronavirus-2(SARS-CoV-2)infection is a new respiratory infectious disease.Patients with chronic kidney disease are at high risk of SARS-CoV-2 infection.Once they develop SARS-CoV-2 infection,the rate of progression to severe illness or even death is much higher than that of the general population.Nirmatrelvir/ritonavir significantly reduce the risk of severe illness and death in patients infected with SARS-CoV-2.In this paper,the dosing regimen and drug interaction of nirmatrelvir/ritonavir in patients with different stages of chronic kidney disease complicated with SARS-CoV-2 infection were reviewed to provide a reference for clinical rational medication for patients with chronic kidney disease.